The ability to assay the effect of genetic variation at the expression level is the first step in studying a range of tauopathies, from diseases caused by specific tau mutations such as those found in FTDP-17, to diseases with strong genetic associations with MAPT as in PD, PSP, and CBD. This evidence concerns the gene MAPT and semantic dementia.